Omalizumab in chronic urticaria lasted a median of three years, and early stopping was mostly for good control

Design

Systematic review and meta-analysis of reconstructed time-to-event data from observational studies

Population

4,516 patients with chronic urticaria in 8 studies

Primary outcome

Omalizumab drug survival and reasons for stopping

Effect

Median 3.1 years (95% CI 2.8–3.4); autoimmune comorbidity HR 2.03 (1.20–3.41) for stopping due to lack of effect

This meta-analysis reconstructed individual patient time-to-stopping data from the published survival curves of eight observational studies, covering 4,516 people with chronic urticaria, about three-quarters with chronic spontaneous urticaria.

Median drug survival was 3.1 years. Over seven years of follow-up, patients stayed on treatment for a mean of 3.75 years. Survival was longer in chronic inducible urticaria (43–49% still on treatment at seven years) than in spontaneous urticaria alone (30%). Early stopping was mainly because the disease was well controlled, and stopping for adverse events was uncommon. Autoimmune comorbidity, mainly thyroid disease, was associated with about twice the risk of stopping for lack of effect, while an atopic background was linked to stopping because of good control.

The data are observational and depend on how each centre decided to stop, so drug survival reflects practice as much as pharmacology. It is still useful counselling material: most patients who respond can expect to taper eventually, and thyroid autoimmunity is worth knowing about before starting. In India, cost limits access, which makes predicting who will respond more valuable. It was published in September 2026.

• Tell patients starting omalizumab that treatment often continues for about three years, and that many stop because the urticaria settles.
• Check thyroid autoantibodies or history of autoimmune thyroid disease; it was linked to stopping for lack of effect.
• Consider an earlier review of response in patients with autoimmune comorbidity.
• Plan a trial of tapering once control is sustained, since control was the commonest reason for stopping.
• Adverse effects rarely led to withdrawal in these studies.

Why it matters

It gives patients a realistic horizon for an expensive injection and flags who is less likely to benefit.

Don't overread it

Drug survival reflects how clinicians chose to stop in these studies, not a controlled measure of efficacy.

The statistics, in plain English

Median drug survival of 3.1 years means half of patients had stopped by then. A hazard ratio of 2.03 (95% CI 1.20–3.41) for autoimmune comorbidity means about twice the rate of stopping for lack of effect; the lower limit of 1.20 means the true increase could be modest. The data were rebuilt from published curves, which is a validated method but less precise than raw patient data.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.